The $3 billion industrial enzyme industry now speaks German: BASF takes Verenium

Verenium Headquarter in San Diego, California
Verenium Headquarter in San Diego, California

BASF grows in biotechnology field and closes the gap on market leaders DuPont and Novozymes in the $3 billion industrial enzyme industry. The German world’s leading chemical company yesterday announced that it has successfully completed the previously announced tender offer to purchase all outstanding shares of common stock of Verenium Corporation, San Diego, California, for US$4.00 per share in cash. The tender offer expired at 9:00 a.m. Eastern Standard Time (USA) on October 31, 2013. As of the expiration of the tender offer, 11,337,044 Verenium shares were validly tendered and not withdrawn in the tender offer, representing approximately 71% of Verenium’s outstanding shares, according to the depositary for the tender offer. Based on all outstanding shares and including all net financial liabilities, the enterprise value would be approximately US$62 million (approximately €48 million).

Continue reading

New turmoil in the $3 billion industrial enzyme industry: Basf agreed to buy Verenium

Kurt Bock, Ceo of Basf
Kurt Bock, Ceo of Basf

Basf, the world’s biggest chemical maker based in Ludwigshafen (Germany), agreed to buy Verenium Corp., a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, to pursue growth in biotechnology and close the gap on market leaders DuPont and Novozymes in the $3 billion industrial enzyme industry.

Continue reading